China Approved the First Vaccine Ad5-nCoV Patent, Developed by Chen Wei, Academician of the Chinese Academy of Engineering : 99.5% of Vaccinators Produce Specific Antibodies

According to China News Agency, the coronavirus pneumonia vaccine developed by the Academy of Military Medicine of the Chinese Academy of Military Sciences successfully applied for a patent, becoming China's first patent for a vaccine against coronavirus pneumonia. The vaccine is currently undergoing Phase III international clinical trials.

According to sources from the State Intellectual Property Office of China, the vaccine is named Ad5-nCoV, which was jointly declared by Chen Wei's team and Chinese biotechnology company Kangsino Bio. The vaccine patent was applied for in March this year, and the patent was granted on August 11. It is China's first coronavirus pneumonia vaccine patent.

China media reported that Chen Wei led a team of military medical experts to Wuhan in January and began to study the pathogen transmission variation of the Wuhan pneumonia virus, rapid detection technology, etc., and then began to develop a vaccine for coronavirus pneumonia. The vaccine has entered the first and second phase clinical trials both domestically and internationally. The results of the second phase clinical trial showed that after 28 days of a single vaccination of 508 volunteer participants, 99.5% of them developed specific antibodies and 89% developed specific T-cell immune responses. The vaccine is currently undergoing Phase III international clinical trials.

The developer is the director of the research institute and an academician of the Chinese Academy of Engineering. Chen Wei is the director and researcher of the Institute of Bio-engineering of the Academy of Military Medical Sciences. She holds the rank of major general. She is a member of the Communist Party of China and an academician of the Chinese Academy of Engineering. This year, she was awarded the national honorary title of 'People's Hero'. She developed the Chinese army's first SARS prevention biological new drug 'recombinant human interferon ω', and the world's first Ebola vaccine approved for a new drug certificate.

Zhong Nanshan, head of the high-level expert group of the National Health Commission, said when attending the 'Sino-Russian Cooperative Epidemic Prevention and Control Academic Exchange Conference' today. He noted that Russia's vaccine research and development is progressing rapidly, and China and Russia have plans to jointly conduct vaccine clinical trials.

Russian President Vladimir Putin announced on last Tuesday that the Ministry of Health of the country has approved the widespread emergency application of the new Russian-made coronavirus pneumonia vaccine 'Sputnik V', which will be launched as soon as the end of this month. However, some experts pointed out that the vaccine has not been tested on a large scale, and its safety and effectiveness have not been determined.